Dr Reddys Laboratories Share Price
Sector: Biotechnology & Drugs
6370.05 +18.55 (0.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6282.8
Today’s High
6376.6
52 Week Low
5042.65
52 Week High
6505.5
6357.45 +3.75 (0.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6284.25
Today’s High
6377.7
52 Week Low
5076.25
52 Week High
6505.9
Key Metrics
- Market Cap (In Cr) 106624.7
- Beta 0.26
- Div. Yield (%) 0.62
- P/B 3.77
- TTM P/E 18.37
- Peg Ratio -22.48
- Sector P/E 31.64
- D/E 0.07
- Open Price 6359.95
- Prev Close 6351.5
Dr Reddys Laboratories Analysis
Price Analysis
-
1 Week4.93%
-
3 Months1.65%
-
6 Month9.14%
-
YTD9.59%
-
1 Year23.14%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 6
- 5
- 5
- 5
- Buy
- 5
- 6
- 6
- 6
- Hold
- 9
- 9
- 9
- 11
- Sell
- 8
- 8
- 8
- 8
- Strong Sell
- 4
- 4
- 4
- 3
- Total
- 32
- 32
- 32
- 33
Dr Reddys Laboratories News
Dr Reddys Laboratories Q4 Results Live : profit rise by 36.41% YOY
1 min read . 09 May 2024New businesses and partnerships hold the key to Dr Reddy's growth
2 min read . 08 May 2024Dr Reddys Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 28011.1
- Selling/ General/ Admin Expenses Total
- 11869
- Depreciation/ Amortization
- 1470
- Total Operating Expense
- 21395.6
- Operating Income
- 6615.5
- Net Income Before Taxes
- 7201
- Net Income
- 5577.9
- Diluted Normalized EPS
- 327.52
- Period
- 2024
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 1441.77
- Period
- 2024
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
- Period
- 2023
- Total Revenue
- 24669.7
- Selling/ General/ Admin Expenses Total
- 8204.8
- Depreciation/ Amortization
- 1250.2
- Total Operating Expense
- 19449.8
- Operating Income
- 5219.9
- Net Income Before Taxes
- 6048.5
- Net Income
- 4507.3
- Diluted Normalized EPS
- 279.44
- Period
- 2023
- Total Assets
- 32285.1
- Total Liabilities
- 8999
- Total Equity
- 23286.1
- Tangible Book Valueper Share Common Eq
- 1183.6
- Period
- 2023
- Cashfrom Operating Activities
- 5887.5
- Cashfrom Investing Activities
- -4137.3
- Cashfrom Financing Activities
- -2686.1
- Net Changein Cash
- -907.3
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 165.95
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 142.73
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 818.04
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 187.62
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 749.67
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2019
- Total Revenue
- 15448.2
- Selling/ General/ Admin Expenses Total
- 5839.9
- Depreciation/ Amortization
- 1134.8
- Total Operating Expense
- 13404.8
- Operating Income
- 2043.4
- Net Income Before Taxes
- 2292
- Net Income
- 1950
- Diluted Normalized EPS
- 111.64
- Period
- 2019
- Total Assets
- 22465.6
- Total Liabilities
- 8442
- Total Equity
- 14023.6
- Tangible Book Valueper Share Common Eq
- 559.81
- Period
- 2019
- Cashfrom Operating Activities
- 2870.4
- Cashfrom Investing Activities
- -772.7
- Cashfrom Financing Activities
- -2132.6
- Net Changein Cash
- -31.4
- Period
- 2024-03-31
- Total Revenue
- 7113.8
- Selling/ General/ Admin Expenses Total
- 3207.8
- Depreciation/ Amortization
- 367.7
- Total Operating Expense
- 5650.3
- Operating Income
- 1463.5
- Net Income Before Taxes
- 1605.2
- Net Income
- 1309.8
- Diluted Normalized EPS
- 77.68
- Period
- 2024-03-31
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 1441.77
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
- Period
- 2023-12-31
- Total Revenue
- 7236.8
- Selling/ General/ Admin Expenses Total
- 3026.7
- Depreciation/ Amortization
- 373.5
- Total Operating Expense
- 5587.2
- Operating Income
- 1649.6
- Net Income Before Taxes
- 1829.1
- Net Income
- 1380.9
- Diluted Normalized EPS
- 83.31
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 6902.6
- Selling/ General/ Admin Expenses Total
- 2885.8
- Depreciation/ Amortization
- 375.5
- Total Operating Expense
- 5171.4
- Operating Income
- 1731.2
- Net Income Before Taxes
- 1916.7
- Net Income
- 1482.2
- Diluted Normalized EPS
- 84.6
- Period
- 2023-09-30
- Total Assets
- 34809.4
- Total Liabilities
- 9312.6
- Total Equity
- 25496.8
- Tangible Book Valueper Share Common Eq
- 1277.13
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 2917.6
- Cashfrom Investing Activities
- -1275.3
- Cashfrom Financing Activities
- -851.2
- Net Changein Cash
- 775.6
- Period
- 2023-06-30
- Total Revenue
- 6757.9
- Selling/ General/ Admin Expenses Total
- 2757.1
- Depreciation/ Amortization
- 353.3
- Total Operating Expense
- 4995.1
- Operating Income
- 1762.8
- Net Income Before Taxes
- 1850
- Net Income
- 1405
- Diluted Normalized EPS
- 81.95
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 6315.2
- Selling/ General/ Admin Expenses Total
- 2829.2
- Depreciation/ Amortization
- 315.5
- Total Operating Expense
- 5096.7
- Operating Income
- 1218.5
- Net Income Before Taxes
- 1329.2
- Net Income
- 960.2
- Diluted Normalized EPS
- 60.01
- Period
- 2023-03-31
- Total Assets
- 32285.1
- Total Liabilities
- 8999
- Total Equity
- 23286.1
- Tangible Book Valueper Share Common Eq
- 1183.6
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5887.5
- Cashfrom Investing Activities
- -4137.3
- Cashfrom Financing Activities
- -2686.1
- Net Changein Cash
- -907.3
- Period
- 2022-12-31
- Total Revenue
- 6789.8
- Selling/ General/ Admin Expenses Total
- 2836.5
- Depreciation/ Amortization
- 323.7
- Total Operating Expense
- 5175
- Operating Income
- 1614.8
- Net Income Before Taxes
- 1637.7
- Net Income
- 1243.9
- Diluted Normalized EPS
- 75.37
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Dr Reddys Laboratories Technical
Moving Average
SMA
- 5 Day6171.03
- 10 Day6086.03
- 20 Day6029.93
- 50 Day6027.65
- 100 Day6112.49
- 300 Day5864.52
Dr Reddys Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Cipla
- 1489
- 10.1
- 0.68
- 1581.7
- 997
- 120221.11
- Zydus Lifesciences
- 1069.5
- 2.55
- 0.24
- 1171.95
- 564.05
- 107591.7
- Dr Reddys Laboratories
- 6370.05
- 18.55
- 0.29
- 6505.5
- 5042.65
- 106079.47
- Torrent Pharmaceuticals
- 2833.55
- 54.15
- 1.95
- 2977.1
- 1771.35
- 95904.33
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Cipla
- 28.06
- 4.48
- 13.5
- 12.66
- Zydus Lifesciences
- 27.8
- 5.36
- 15.65
- 14.33
- Dr Reddys Laboratories
- 19.04
- 3.68
- 16.73
- 14.63
- Torrent Pharmaceuticals
- 58.84
- 13.68
- 20.64
- 13.17
- Lupin
- 37.82
- 5.05
- 2.51
- 2.04
Dr Reddys Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 10-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results
- 28-Oct-22
- Quarterly Results
- 28-Jul-22
- Quarterly Results
- 19-May-22
- Audited Results & Final Dividend
- 28-Jan-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 16-Nov-23
- 16-Oct-23
- POM
- 27-Jul-23
- 10-May-23
- AGM
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-May-24
- -
- -
- 40
- 10-May-23
- -
- 11-Jul-23
- 40
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)